Advancing Partners & Communities works to address barriers to health service access by building the capacity of local organizations in Ghana and supporting the creation of local and sustainable initiatives.
MCSP has helped to build the capacity of health personnel to manage and deliver routine immunization services in more than 400 health facilities across 11 districts in Uganda.
On May 23rd, JSI’s Advancing Partners & Communities hosted a closing event to celebrate its success Benin. Since 2012, the program has helped roll out a package of high-impact primary health care interventions and expand access to injectable contraception at the community level in 10 USAID priority health zones.
In Tanzania, bicycles help community case workers reach HIV-affected families and link vulnerable children and their family to health services.
JSI has been supporting Ministries of Health in eight countries as they plan for and introduce this life-saving vaccine, and in doing so has learned a lot about how to reach adolescent girls.
JSI and MCSP worked with stakeholders at multiple levels of the health system, assisting the local government to improve planning for vaccine delivery, and developing multiple strategies to try to raise and maintain Tabora’s MCV 2 coverage rate.
The AIDSFree project, implemented by JSI and the Elizabeth Glaser Pediatric AIDS Foundation, designed a program to help pregnant girls, adolescent mothers overcome barriers to education and employment.
In July 2018, 70 village health team (VHT) members and 12 health workers in Uganda were trained to teach clients to self-inject subcutaneously administered depot medroxyprogesterone acetate (DMPA-SC) through the JSI led Advancing Partners & Communities Project.
A team from JSI Research & Training Institute, Inc. (JSI) and inSupply Health has been implementing cStock, a methodology to strengthen the supply of medicines for community health volunteers.
JSI-trained integrated community malaria volunteers (IMCVs) are at the frontlines of patient identification and treatment follow-up for tuberculosis (TB). These IMCVs are able to reach populations that would otherwise not have access to life-saving health services due to limited human resources.